Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.
Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.
Yilmaz
B T
BT
Department of Pediatrics, Pediatric Hematology Unit, Baskent University Faculty of Medicine, 6.cad No:72/3 06490, Bahcelievler, Ankara, Turkey.
Alioglu
B
B
Ozyurek
E
E
Akay
H T
HT
Mercan
S
S
Ozbek
N
N
D016063:Blood Loss, Surgical / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures / Q000379:methods; D002648:Child; D003029:Coagulants / Q000627:therapeutic use*; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013915:Thrombasthenia / Q000188:drug therapy / Q000601:surgery*
D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa